Clinical Trial Update: A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and preliminary efficacy of combining Golidocitinib with Tislelizumab and chemotherapy as first-line treatment fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• Golidocitinib (golidocitinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Status: RECRUITING